Kymera Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Net Income	-146.96	-154.81	-100.22	-54.64	-41.25	Upgrade
Depreciation & Amortization	3.57	2.98	2.4	1.76	0.83	Upgrade
Share-Based Compensation	43.12	35.48	24.97	5.19	1.2	Upgrade
Other Operating Activities	-2.55	-36.73	-56.1	126.77	57.13	Upgrade
Operating Cash Flow	-102.83	-153.09	-128.95	88.13	17.91	Upgrade
Operating Cash Flow Growth	-	-	-	392.21%	-	Upgrade
Capital Expenditures	-34.48	-2.84	-1.6	-9.1	-0.53	Upgrade
Change in Investments	174.37	23.36	-98.24	-413.49	-15.95	Upgrade
Investing Cash Flow	139.89	20.52	-99.84	-422.59	-16.49	Upgrade
Share Issuance / Repurchase	4.27	154.13	251.13	196.84	0.07	Upgrade
Debt Issued / Paid	-0.08	-1.13	-0.85	-0.55	-0.37	Upgrade
Other Financing Activities	-	-	-	92.98	35.21	Upgrade
Financing Cash Flow	4.19	153	250.28	289.26	34.91	Upgrade
Net Cash Flow	41.25	20.43	21.5	-45.2	36.33	Upgrade
Free Cash Flow	-137.31	-155.92	-130.54	79.03	17.37	Upgrade
Free Cash Flow Growth	-	-	-	354.92%	-	Upgrade
Free Cash Flow Margin	-174.71%	-332.98%	-179.24%	232.22%	592.13%	Upgrade
Free Cash Flow Per Share	-2.35	-2.89	-2.72	4.55	10.23	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).